Warum Viking Therapeutics möglicherweise „auf etwas ganz Erstaunliches gestoßen ist“
Eli Lilly (LLY) und Novo Nordisk (NVO) sind im vergangenen Jahr dank ihrer Blockbuster-Medikamente GLP-1 zur Behandlung von Fettleibigkeit zu ...
Eli Lilly (LLY) und Novo Nordisk (NVO) sind im vergangenen Jahr dank ihrer Blockbuster-Medikamente GLP-1 zur Behandlung von Fettleibigkeit zu ...
Die Aktie von Novo Nordisk (NVO) notierte am Donnerstag trotz starker Ergebnisse für das erste Quartal im Minus und übertraf ...
Wie Sie vielleicht kürzlich erfahren haben, handelt es sich bei den „Magnificent Seven“ um eine Gruppe mächtiger Aktien, darunter Nvidia, ...
North Carolina is cutting off coverage of anti-obesity medications for state employees, citing soaring costs and a lack of agreement ...
Copyright © 2024 DerInformant.
DerInformant.com is not responsible for the content of external sites.
DerInformant.com is a proud member of BXL MEDIA
Copyright © 2024 DerInformant.
DerInformant.com is not responsible for the content of external sites.
DerInformant.com is a proud member of BXL MEDIA
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.